Sichenzia Ross Ference LLP Represents Immuron Limited in $20 Million Registered Direct Offering
Press Release – New York, NY – July 23, 2020 – Sichenzia Ross Ference LLP today announced that it represented Immuron Limited (NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, in a registered direct offering of 1,066,668 American Depositary Shares (“ADSs”), each ADS representing 40 of the Company’s ordinary shares, at a purchase price of $18.75 per ADS for gross proceeds of approximately $20 million.
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
The offering was made pursuant to a shelf registration statement on Form F-3 (File No. 333-230762) previously declared effective by the U.S. Securities and Exchange Commission on April 17, 2019.
The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia, Darrin Ocasio, and Avital Perlman, counsel Jeffrey Cahlon, and associate Matthew Siracusa.